United Therapeutics
Clinical trials sponsored by United Therapeutics, explained in plain language.
Develops therapies for pulmonary arterial hypertension and other chronic diseases.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug aims to help lungs and heart work better during exercise
Disease control TerminatedThis phase 3 trial tests whether ralinepag, an oral medication, can improve exercise capacity in people with pulmonary arterial hypertension (PAH) who have recently started PAH therapy. Participants take ralinepag or a placebo for 28 weeks, and their peak oxygen consumption durin…
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Inhaled treprostinil safety trial for PH-COPD ends early
Disease control TerminatedThis study looked at the long-term safety of an inhaled drug called treprostinil in people who have both pulmonary hypertension (high blood pressure in the lungs) and COPD. It included 41 adults who had already completed a previous study. The trial was terminated early, and the m…
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC